CJC-1295 without DAC 5mg

Description

CJC-1295 Without DAC Technical Overview

CJC-1295 without DAC is commonly used as a commercial designation for Modified GRF(1–29), a synthetic 29-amino-acid analogue of growth hormone-releasing hormone.

The modified sequence has been developed for experimental investigations of peptide stability and GHRH receptor signaling.

Unlike CJC-1295 with DAC, Modified GRF(1–29) lacks the albumin-binding Drug Affinity Complex.

Compound Specifications

Storage and Handling

• Use manufacturer-validated stability recommendations.
• Protect from moisture and contamination.
• Follow appropriate laboratory handling procedures.

Lyophilized Format

Modified GRF(1–29) may be manufactured in lyophilized form. Storage conditions depend on the supplied preparation.

Research Use Disclaimer

This peptide is not FDA-approved for human therapeutic use. Not intended for human or veterinary administration.

Frequently Asked Questions

What Is CJC-1295 Without DAC?

A commercial designation generally associated with Modified GRF(1–29).

How Many Amino Acids Does It Contain?

The modified GHRH fragment contains 29 residues.

Which Receptor Does It Target?

GHRHR.

Does It Contain a Drug Affinity Complex?

No.

Is It FDA-Approved?

No.

Research Overview

Modified GRF(1–29) is studied in relation to growth hormone-releasing hormone receptor activity.

GHRHR Signaling

Research examines receptor activation and downstream signaling.

Peptide Structure

The modified 29-residue sequence supports investigations into the relationship between amino acid substitutions and peptide properties.

Endocrine Research

Laboratory research examines GHRH-associated signaling pathways.

Research Applications

References

1. Modified GRF(1–29) Research — PubMed.

Certificate of Analysis (COA)

Documentation should verify the complete peptide sequence, identity, purity, and content. Peptide Lives.